650TiP PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa)

Adding docetaxel or androgen receptor signalling inhibitor (ARSI) at start of androgen deprivation therapy (ADT) for mPCa improves progression-free survival (PFS) and overall survival (OS). Duration of benefit is variable; although serum PSA at 7 months (mth) associates with differential outcome, physicians still lack the tools to identify who will develop early resistance and require alternative or intensified...